Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05001269 · ClinicalTrials.gov registry record · Phase 2
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
A Phase 2 study, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT05001269 is a Phase 2 study that has completed, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 27 participants.
The verdict
NCT05001269, a Phase 2 study, has completed, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
Interventions
- DRUG nedosiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-02-22 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05001269
The ClinicalTrials.gov registry entry for NCT05001269 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nedosiran is the first listed.
NCT05001269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05001269 about?
NCT05001269 is a clinical study titled "Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function". The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
What is the current status of trial NCT05001269?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2022-02-22. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05001269?
The interventions under investigation include: nedosiran (DRUG).
Who is sponsoring clinical trial NCT05001269?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.